Integra LifeSciences (NASDAQ:IART) Earns Hold Rating from Argus

Integra LifeSciences (NASDAQ:IART)‘s stock had its “hold” rating restated by investment analysts at Argus in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports.

A number of other research analysts have also weighed in on the stock. Citigroup decreased their target price on shares of Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a research note on Wednesday, March 11th. Wells Fargo & Company raised shares of Integra LifeSciences to a “hold” rating in a research note on Wednesday, March 18th. Wall Street Zen lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a report on Friday, March 27th. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $14.20.

Integra LifeSciences Price Performance

Shares of IART opened at $10.84 on Wednesday. The business’s 50-day moving average is $10.23 and its two-hundred day moving average is $12.02. The company has a market capitalization of $844.87 million, a P/E ratio of -1.61 and a beta of 1.06. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.46 and a current ratio of 2.54. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $17.54.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Thursday, February 26th. The life sciences company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.04. The firm had revenue of $434.93 million for the quarter, compared to analysts’ expectations of $429.62 million. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The company’s quarterly revenue was down 1.7% on a year-over-year basis. During the same period last year, the firm earned $0.97 EPS. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Research analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current year.

Institutional Trading of Integra LifeSciences

Institutional investors have recently added to or reduced their stakes in the stock. Allianz Asset Management GmbH increased its holdings in Integra LifeSciences by 88.7% in the 3rd quarter. Allianz Asset Management GmbH now owns 433,738 shares of the life sciences company’s stock valued at $6,215,000 after purchasing an additional 203,834 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new stake in Integra LifeSciences in the 3rd quarter valued at approximately $2,407,000. SG Americas Securities LLC acquired a new stake in Integra LifeSciences in the 4th quarter valued at approximately $4,722,000. Assenagon Asset Management S.A. increased its holdings in Integra LifeSciences by 15.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 526,302 shares of the life sciences company’s stock valued at $6,537,000 after purchasing an additional 71,950 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Integra LifeSciences in the 2nd quarter valued at approximately $765,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.